Ghost Tree Capital’s Mersana Therapeutics MRSN Stock Holding History

Ghost Tree Capital’s Portfolio MRSN Stock Details MRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-2,450	Closed	-$77.8K	–	64
2023 Q3	$77.8K	Hold	2,450	–	–	0.03%	69
2023 Q2	$202K	Buy	+2,450	New	+$358K	0.07%	56
2021 Q3	–	Sell	-18,000	Closed	-$6.11M	–	66
2021 Q2	$6.11M	Hold	18,000	–	–	1.68%	22
2021 Q1	$7.28M	Sell	18,000 -6,000	-25%	-$2.91M	1.71%	20
2020 Q4	$16M	Sell	24,000 -18,000	-43%	-$10M	3.56%	10
2020 Q3	$19.6M	Buy	42,000 +17,000	+68%	+$8.59M	5.65%	4
2020 Q2	$14.6M	Sell	25,000 -55,000	-69%	-$18.8M	3.86%	8
2020 Q1	$11.7M	Buy	80,000 +48,000	+150%	+$8.39M	3.09%	10
2019 Q4	$4.58M	Buy	+32,000	New	+$2.34M	0.87%	37
2018 Q3	–	Sell	-24,000	Closed	-$10.7M	–	59
2018 Q2	$10.7M	Buy	24,000 +12,870	+116%	+$5.65M	3.15%	10
2018 Q1	$4.39M	Buy	+11,130	New	+$4.39M	0.89%	36

Other funds holding MRSN

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Ghost Tree Capital's MRSN Position: Q4 2023 in Review

Ghost Tree Capital sold out of Mersana Therapeutics (MRSN) in Q4 2023, closing a stake of 2,450 shares — an estimated $77.8K sold.

Ghost Tree Capital first reported a position in MRSN in Q1 2018 and held it in 11 quarters. The position peaked at $19.6M in Q3 2020. 105 funds tracked by Wall St. Rank hold MRSN as of Q4 2023.

Ghost Tree Capital reported no remaining Mersana Therapeutics position as of Q4 2023 after selling out during the quarter.
Ghost Tree Capital sold 2,450 Mersana Therapeutics shares in Q4 2023, an estimated $77.8K.
Ghost Tree Capital first reported a position in Mersana Therapeutics in Q1 2018 and held it in 11 quarters.
Ghost Tree Capital's Mersana Therapeutics position peaked at $19.6M in Q3 2020.
105 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q4 2023.

Based on Ghost Tree Capital's 13F filing for Q4 2023, filed 14 Feb 2024.